Patents by Inventor Guenter Mueller

Guenter Mueller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of erg4 mutants for expressing mammalian glucose transporters
    Patent number: 7244821
    Abstract: The invention relates to yeast strains in which a human GLUT4 transport or a human GLUT1 transporter can be functionally expressed and to particular GLUT4 transport proteins which can be functionally expressed particularly readily in yeast strains.
    Type: Grant
    Filed: September 10, 2003
    Date of Patent: July 17, 2007
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Guenter Mueller, Silke Dlugai, Doerthe Voss, Eckhard Boles
  • PIM-3 KINASE AS A TARGET FOR TYPE 2 DIABETES MELLITUS
    Publication number: 20070154919
    Abstract: The invention relates to isolated nucleic acid molecules and to host cells comprising such nucleic acid molecules. Moreover, the invention relates to a polypeptide having PIM-3 activity and having a definite amino acid sequence, as well as to the use of PIM-3 as a screening agent for identifying anti-type 2 diabetes mellitus drugs and for preparing a medicament for the treatment of insulin resistance or type 2 diabetes mellitus.
    Type: Application
    Filed: December 12, 2006
    Publication date: July 5, 2007
    Applicant: Sanofi-Aventis Deutschland GmbH
    Inventors: Marc Korn, Guenter Mueller, Rudolf Schneider, Georg Tschank
  • PIM-3 kinase as a target for type 2 diabetes mellitus
    Patent number: 7227006
    Abstract: The invention relates to isolated nucleic acid molecules and to host cells comprising such nucleic acid molecules. Moreover, the invention relates to a polypeptide having PIM-3 activity and having a definite amino acid sequence, as well as to the use of PIM-3 as a screening agent for identifying anti-type 2 diabetes mellitus drugs and for preparing a medicament for the treatment of insulin resistance or type 2 diabetes mellitus.
    Type: Grant
    Filed: January 21, 2003
    Date of Patent: June 5, 2007
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Marcus Korn, Guenter Mueller, Rudolf Schneider, Georg Tschank
  • GLIMEPIRIDE- AND INSULIN-INDUCED GLYCOSYLPHOSPHATIDYLINOSITOL-SPECIFIC PHOSPHOLIPASE C REGULATION
    Publication number: 20070111263
    Abstract: The present invention relates to a method for identification of a chemical compound which modulates the activity of mammalian GPI-PLC wherein a] a mammalian cell is incubated with glimepiride; b] hcDIGs of the cells of a] are prepared; c] the hcDIGs from b] are incubated with a chemical compound; d] the activity of the GPI-PLC from the hcDIGs of c] is determined.
    Type: Application
    Filed: August 14, 2006
    Publication date: May 17, 2007
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Guenter MUELLER, Wendelin FRICK, Rudolf SCHNEIDER
  • Substituted an unsubstituted benzooxathiazoles and compounds derived therefrom
    Patent number: 7211592
    Abstract: The invention relates to substituted and unsubstituted 3H-benzo[1,2,3]oxathiazole 2,2-dioxides, 1,3-dihydrobenzo[1,2,5]thiadiazole 2,2-dioxides and 1,3-dihydro-benzo[c]isothiazole 2,2-dioxides, to their preparation and to their use in medicaments.
    Type: Grant
    Filed: September 13, 2004
    Date of Patent: May 1, 2007
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Stefan Petry, Karl-Heinz Baringhaus, Swen Hoelder, Guenter Mueller
  • Bicyclic inhibitors of hormone sensitive lipase
    Patent number: 7208504
    Abstract: Benzotriazoles of formula I in which R1 to R8 have the abovementioned meanings and process for their preparation are described. The compounds show an inhibitory effect on hormone-sensitive lipase.
    Type: Grant
    Filed: October 14, 2003
    Date of Patent: April 24, 2007
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Stefan Petry, Karl-Heinz Baringhaus, Norbert Tennagels, Guenter Mueller, Hubert Heuer
  • PYRIDAZINONE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND THEIR USE AS PHARMACEUTICALS
    Publication number: 20070088041
    Abstract: The present invention relates to compounds according to the general formula (I), with the definitions of the substituents X, R1 and R2 given below in the text, as well as their physiologically acceptable salts, methods for producing these compounds and their use as pharmaceuticals. These compounds are kinase inhibitors, in particular inhibitors of the kinase GSK-3?(glycogen synthase kinase-3?).
    Type: Application
    Filed: October 24, 2006
    Publication date: April 19, 2007
    Applicant: Sanofi-aventis Deutschland GmbH
    Inventors: Swen Hoelder, Karl Schoenafinger, David Will, Hans Matter, Guenter Mueller, Martin Bossart
  • Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
    Patent number: 7094794
    Abstract: Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use. The invention relates to compounds of the formula I in which the radicals have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example as medicaments for lowering the blood glucose and for the prevention and treatment of diabetes.
    Type: Grant
    Filed: July 27, 2004
    Date of Patent: August 22, 2006
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Stefan Petry, Karl-Heinz Baringhaus, Norbert Tennagels, Guenter Mueller
  • Phosophoinositoglycan binding proteins
    Publication number: 20060160142
    Abstract: The invention refers to a protein from plasma membrane of adipocytes. The protein has specific binding affinity to phosphoinositoylglycans. It regulates glucose uptake by circumventing the insulin signaling cascade.
    Type: Application
    Filed: March 16, 2006
    Publication date: July 20, 2006
    Applicant: Sanofi-Aventis Deutschland GmbH
    Inventors: Guenter Mueller, Wendelin Frick, Stefan Petry, Rudolf Schneider, Matthias Urmann
  • Phosophoinositoglycan binding proteins
    Patent number: 7049416
    Abstract: The invention refers to a protein from plasma membrane of adipocytes. The protein has specific binding affinity to phosphoinositoylglycans. It regulates glucose uptake by circumventing the insulin signaling cascade.
    Type: Grant
    Filed: July 3, 2003
    Date of Patent: May 23, 2006
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventors: Guenter Mueller, Wendelin Frick, Stefan Petry, Rudolf Schneider, Matthias Urmann
  • Substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadiazol-2-ones, pharmaceutical composition and method for treating obesity thereof
    Patent number: 6900233
    Abstract: A substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadiazol-2-one, compound of formula 1, wherein R1, R2, R3, R4 and R5 are as defined herein, pharmaceutical composition comprising the compound and use of the compound for inhibiting pancreatic lipase, or the prophylaxis or treatment of obesity are described.
    Type: Grant
    Filed: February 27, 2003
    Date of Patent: May 31, 2005
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Karl Schoenafinger, Stefan Petry, Günter Müller, Armin Bauer, Hubert Otto Heuer
  • Use of Saccharomyces cerevisiae Erg4 mutants for expressing mammalian glucose transporters
    Publication number: 20050074845
    Abstract: The invention relates to yeast strains in which a human GLUT4 transport or a human GLUT1 transporter can be functionally expressed and to particular GLUT4 transport proteins which can be functionally expressed particularly readily in yeast strains.
    Type: Application
    Filed: September 10, 2003
    Publication date: April 7, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Guenter Mueller, Silke Dlugai, Doerthe Voss, Eckhard Boles
  • Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
    Publication number: 20050070533
    Abstract: The invention relates to compounds of the formula I in which the radicals have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example as medicaments for lowering the blood glucose and for the prevention and treatment of diabetes.
    Type: Application
    Filed: July 27, 2004
    Publication date: March 31, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Stefan Petry, Karl-Heinz Baringhaus, Norbert Tennagels, Guenter Mueller
  • Thixotropic dispersions of polysuccinimide and their use
    Patent number: 6861398
    Abstract: The present invention relates to stable thixotropic polysuccinimide (PSI) dispersions, known as slurries, and to their use as additives for improving the flow properties of concrete, in oil wells, in acidic gel cleaners, and in drainage systems of tunnel constructions.
    Type: Grant
    Filed: May 21, 2002
    Date of Patent: March 1, 2005
    Assignee: Bayer Aktiengesellschaft
    Inventors: Thomas Klein, Joachim Voss, Holger Schmidt, Fred Ebert, Harry-Günter Müller
  • Substituted an unsubstituted benzooxathiazoles and compounds derived therefrom
    Publication number: 20050043373
    Abstract: The invention relates to substituted and unsubstituted 3H-benzo[1,2,3]oxathiazole 2,2-dioxides, 1,3-dihydrobenzo[1,2,5]thiadiazole 2,2-dioxides and 1,3-dihydrobenzo[c]isothiazole 2,2-dioxides, to their preparation and to their use in medicaments.
    Type: Application
    Filed: September 13, 2004
    Publication date: February 24, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Stefan Petry, Karl-Heinz Baringhaus, Swen Hoelder, Guenter Mueller
  • Pyrimido[5,4-e][1,2,4]triazine-5,7-diones, processes for preparing them and their use
    Publication number: 20040242583
    Abstract: The invention relates to pyrimido[5,4-e][1,2,4]triazine-5,7-diones, pharmaceutically acceptable salts thereof and physiologically functional derivatives.
    Type: Application
    Filed: January 20, 2004
    Publication date: December 2, 2004
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Stefan Petry, Karl-Heinz Barimghaus, Norbert Tennagels, Guenter Mueller
  • Phosophoinositoglycan binding proteins
    Publication number: 20040229278
    Abstract: The invention refers to a protein from plasma membrane of adipocytes. The protein has specific binding affinity to phosphoinositoylglycans. It regulates glucose uptake by circumventing the insulin signaling cascade.
    Type: Application
    Filed: July 3, 2003
    Publication date: November 18, 2004
    Inventors: Guenter Mueller, Wendelin Frick, Stefan Petry, Rudolf Schneider, Matthias Urmann
  • Cable-free medical detection and treatment system
    Patent number: 6782285
    Abstract: A system for medical detection and treatment comprising a number of treatment and/or detection devices which exchange data with each other within the context of a medical treatment, in particular a surgical or radiotherapeutic and/or radiosurgical operation, wherein the data are exchanged via radio interfaces in and/or on the devices.
    Type: Grant
    Filed: November 1, 2001
    Date of Patent: August 24, 2004
    Assignee: BrainLAB AG
    Inventors: Rainer Birkenbach, Günter Müller
  • Novel adenosine analogues and their use as pharmaceutical agents
    Publication number: 20040127434
    Abstract: The present invention relates to compounds according to the general formula (I) 1
    Type: Application
    Filed: June 27, 2003
    Publication date: July 1, 2004
    Inventors: Antony Bigot, Siegfried Stengelin, Gerhard Jaehne, Andreas Herling, Guenter Mueller, Franz Jakob Hock, Michael R. Myers
  • Novel bicyclic inhibitors of hormone sensitive lipase
    Publication number: 20040127484
    Abstract: Benzotriazoles of formula I 1
    Type: Application
    Filed: October 14, 2003
    Publication date: July 1, 2004
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Stefan Petry, Karl-Heinz Baringhaus, Norbert Tennagels, Guenter Mueller, Hubert Heuer